|
|
Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit :
- ventes de produits (88%) ;
- royalties (9,6%) ;
- licences et accords de collaboration (2,4%).
Nombre d'employés : 2 675 personnes.
|
|
|
| 2020 | 2021 | Delta | | Pharmaceutical Products | 2 175.54 | 100% | 1 574.37 | 100% | -27.63% |
| USD en Millions |
|
|
|
| 2020 | 2021 | Delta | | United States | 2 175.54 | 100% | 1 574.37 | 100% | -27.63% |
| USD en Millions |
|
|
|
| Vote  | Nombre | Flottant | Autocontrôle | Flottant Total |
| Action A |
1 |
184 075 643 |
182 570 052 |
99.2% |
0 |
0.0% |
99.2% |
|
|
|
| Nom | Actions | % | | Baker Bros. Advisors LP | 47 101 829 |
25,8% | | Capital Research & Management Co. (International Investors) | 15 465 358 |
8,46% | | Wellington Management Co. LLP | 12 476 025 |
6,82% | | The Vanguard Group, Inc. | 12 000 017 |
6,56% | | Capital Research & Management Co. (Global Investors) | 8 962 644 |
4,90% | | T. Rowe Price Associates, Inc. (Investment Management) | 4 850 955 |
2,65% | | PRIMECAP Management Co. | 4 622 910 |
2,53% | | SSgA Funds Management, Inc. | 3 525 411 |
1,93% | | Cascade Investment LLC | 3 521 088 |
1,93% | | BlackRock Fund Advisors | 3 174 803 |
1,74% |
|
|
|
|
- Nasdaq Global Select Market - Nasdaq 100 / |
|
|
|
|
| - Code Bloomberg : |
|
| - Code Reuters : |
SGEN.O |
| - Code Datastream : |
|
|
|
|
Seagen Inc. Building 3 21823 30th Drive S E WA 98021 Bothell, Washington Téléphone : +1 425 527 4000 Fax : Internet : https://investor.seagen.com |
|
|
Secteur Recherche biotechnologique et médicale - Autres
| | Var. 1janv | Capi. (M$) |
 | SEAGEN INC. | -9.87% | 25 649 |
| | | |
| MODERNA, INC. | -45.81% | 54 740 |
 | LONZA GROUP AG | -27.15% | 42 618 |
| IQVIA HOLDINGS INC. | -27.91% | 38 497 |
| ICON PUBLIC LIMITED COMPANY | -29.74% | 17 688 |
 | CELLTRION, INC. | -25.76% | 16 131 |
| ALNYLAM PHARMACEUTICALS, INC. | -22.00% | 15 655 |
| BIO-TECHNE CORPORATION | -29.54% | 14 301 |
 | PHARMARON BEIJING CO., LTD. | -20.71% | 12 616 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | -38.63% | 11 748 |
| HANGZHOU TIGERMED CONSULTING CO., LTD | -31.63% | 10 986 |
| QIAGEN N.V. | -17.43% | 10 438 |
| BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | 3.77% | 10 159 |
| UNITED THERAPEUTICS CORPORATION | -2.75% | 9 519 |
| SYNEOS HEALTH, INC. | -30.40% | 7 331 |
 | GENSCRIPT BIOTECH CORPORATION | -35.07% | 6 003 |
| IONIS PHARMACEUTICALS, INC. | 29.71% | 5 597 |
| BACHEM HOLDING AG | 0.00% | 5 422 |
| AZENTA, INC. | -32.48% | 5 268 |
| JOINN LABORATORIES (CHINA) CO.,LTD. | -14.88% | 5 189 |
| ALKERMES PLC | 25.97% | 4 788 |
|
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Italiano
Nederlands (Nederland)
Nederlands (België)
bourse
Rapport
